Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb

被引:122
作者
Chappell, LL
Dadachova, E
Milenic, DE
Garmestani, K
Wu, CC
Brechbiel, MW
机构
[1] NIH, Radioimmune & Inorgan Chem Sect, ROB, DCS, Bethesda, MD 20892 USA
[2] NCI, Tumor Immunol & Biol Lab, DBS, NIH, Bethesda, MD 20892 USA
[3] Rel Tek Inc, Rockville, MD USA
关键词
macrocycles; lead-203; radioimmunoconjugate; radioimmunoimaging; radioimmunotherapy;
D O I
10.1016/S0969-8051(99)00086-4
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Radioisotopes of Pb(II) have been of some interest in radioimmunotherapy and radioimmunoimaging (RII). However, the absence of a kinetically stable bifunctional chelating agent for Pb(II) has hampered its use for these applications. Pb-203 (T-1/2 = 52.02 h) has application potential in RII, with a gamma-emission that is ideal for single photon emission computerized tomography, whereas Pb-212 (T-1/2 = 10 h) is a source of highly cytotoxic alpha-particles via its decay to its Bi-212 (T-1/2 = 60 min) daughter. The synthesis of the novel bifunctional chelating agent 2-(4-isothiocyanotobenzyl)-1,4,7,10-tetraaza-1,4,7,10-tetra-(2-carbamoyl methyl)-cyclododecane (4-NCS-Bz-TCMC) is reported herein. The Pb[TCMC](2+) complex was less labile to metal ion release than Pb[DOTA](2-) at pH 3. and below in isotopic exchange experiments. In addition to increased stability to Pb2+ ion release at low pH, the bifunctional TCMC ligand was found to have many other advantages over the bifunctional 1,4,7,10-tetraazacyclodocane-1,4,7,10-tetraacetic acid (DOTA) ligand, These include a shorter and more straightforward synthetic route, a more efficient conjugation reaction to a monoclonal antibody (mAb), with a higher chelate to protein ratio, a higher percent immuroreactivity, and a more efficient radiolabeling reaction of the mAb-ligand conjugate with Pb-203. NUCL MED BIOL 27;1:93-100, 2000. Published by Elsevier Science Inc.
引用
收藏
页码:93 / 100
页数:8
相关论文
共 39 条
[1]   Intraperitoneal radioimmunotherapy of ovarian cancer with Lu-177-CC49: A phase I/II study [J].
Alvarez, RD ;
Partridge, EE ;
Khazaeli, MB ;
Plott, G ;
Austin, M ;
Kilgore, L ;
Russell, CD ;
Liu, TP ;
Grizzle, WE ;
Schlom, J ;
LoBuglio, AF ;
Meredith, RF .
GYNECOLOGIC ONCOLOGY, 1997, 65 (01) :94-101
[2]   Restoration of catalytic activity by replacement of a coordinated amide group: Synthesis and laser-induced luminescence studies of the phosphate diester transesterification catalyst [Eu(NBAC)](3+) [J].
Amin, S ;
Voss, DA ;
Horrocks, WD ;
Morrow, JR .
INORGANIC CHEMISTRY, 1996, 35 (26) :7466-+
[3]   LANTHANIDE(III) TETRAAMIDE MACROCYCLIC COMPLEXES AS SYNTHETIC RIBONUCLEASES - STRUCTURE AND CATALYTIC PROPERTIES OF [LA(TCMC)(CF3SO3)(ETOH)](CF3SO3)(2) [J].
AMIN, S ;
MORROW, JR ;
LAKE, CH ;
CHURCHILL, MR .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION IN ENGLISH, 1994, 33 (07) :773-775
[4]   STABILITY ENHANCEMENT OF HEAVY-METAL-MACROCYCLE COMPLEXES VIA PENDANT AMIDE COORDINATION [J].
CARLTON, L ;
HANCOCK, RD ;
MAUMELA, H ;
WAINWRIGHT, KP .
JOURNAL OF THE CHEMICAL SOCIETY-CHEMICAL COMMUNICATIONS, 1994, (08) :1007-1008
[5]   BIFUNCTIONAL ANTIBODIES FOR RADIOIMMUNOTHERAPY [J].
CHATAL, JF ;
FAIVRECHAUVET, A ;
BARDIES, M ;
PELTIER, P ;
GAUTHEROT, E ;
BARBET, J .
HYBRIDOMA, 1995, 14 (02) :125-128
[6]  
COLCHER D, 1987, CANCER RES, V47, P4218
[7]  
COLCHER D, 1988, CANCER RES, V48, P4597
[8]   SYNTHESIS OF A KINETICALLY STABLE Y-90 LABELED MACROCYCLE ANTIBODY CONJUGATE [J].
COX, JPL ;
JANKOWSKI, KJ ;
KATAKY, R ;
PARKER, D ;
BEELEY, NRA ;
BOYCE, BA ;
EATON, MAW ;
MILLAR, K ;
MILLICAN, AT ;
HARRISON, A ;
WALKER, C .
JOURNAL OF THE CHEMICAL SOCIETY-CHEMICAL COMMUNICATIONS, 1989, (12) :797-798
[9]  
DADACHOVA E, IN PRESS NUCL MED BI
[10]  
FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0